ProCE Banner Activity

Premium Education

CE

Migraine: Diagnosis, Treatment Strategies and an Update of the Recent Therapeutic Advances

Video

1.00 Nursing contact hour

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: February 28, 2022

Expiration: February 28, 2025

Course Fee

$30.00

Share

Additional Information

Program Medium

This program has been made available online.

This activity is available for free to members of NASP. Contact NASP for details.


 

A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). 
 

Activity Description

Migraine is a disabling neurological disorder affecting millions of people in the United States and is associated with significant personal and societal burden. It can significantly impact the individual’s quality of life and overall health. Despite its major impact, it continues to be underdiagnosed and subsequently not well treated and many patients resort to inappropriate self-medication. Recent advances have been made in identifying new migraine targets as well as the introduction of new classes of pharmacological options. Pharmacists and nurses play an important role in migraine management and a good understanding of these new advances and overall strategies for the treatment of migraine will enable them to effectively educate patients regarding the appropriate use of the available treatment. This activity will provide a review of the migraine disorder, available treatment options and highlights the recent therapeutic advancements.

Target Audience

The target audience for this activity includes pharmacists and nurses.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the epidemiology, risk factors, and pathology of migraine.
  • Discuss the screening, diagnosis, and types of migraine.
  • Outline treatment regimens for migraine and incorporation of newer preventative medications.
  • Discuss counseling strategies to maximize compliance and adherence.

Faculty

Mitra Habibi, PharmD
Clinical Associate Professor
Neuroscience Clinical Pharmacist
University of Illinois at Chicago

CME/CE Accreditation

Release Date: February 28, 2022
Expiration Date: February 28, 2025

ACPE Credit Designation (Pharmacist CE)This CE activity is jointly provided by ProCE, LLC and the National Association of Specialty Pharmacy (NASP). ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-22-035-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
 

Joint Accreditation StatementIn support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 Nursing Continuing EducationThe maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
 

Disclosure

Clinical Care Options, LLC (CCO) and ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO and ProCE policy. CCO and ProCE are committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty and planners reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Mitra Habibi, PharmD, has received consulting fees from LexiComp Drug Information.
CCO and ProCE Staff have no relevant conflicts of interest to report.
Kanesha Kirkwood, PharmD, has no relevant conflicts of interest to report.
Robin Wanous-Williamson (nurse planner) has no relevant conflicts of interest to report.

Potential conflicts of interest were resolved with a peer review process provided by Kanesha Kirkwood, PharmD.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Funding

This continuing education activity is supported by an educational grant from AllianceRx Walgreens Prime. 

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.